Calculate your SIP ReturnsExplore

Dr Reddy’s USA Secures Exclusive Rights for Cyclophosphamide Injection in the US

20 June 20243 mins read by Angel One
Dr Reddy's USA partners with Ingenus to exclusively market Cyclophosphamide Injection in the US, sharing profits without additional payments.
Dr Reddy’s USA Secures Exclusive Rights for Cyclophosphamide Injection in the US
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

On June 12, 2024, Dr Reddy’s Laboratories Ltd informed the stock exchanges that the company’s step down wholly owned subsidiary, Dr Reddy’s Laboratories, Inc. (Dr Reddy’s USA), and Ingenus Pharmaceuticals, LLC (Ingenus), a Delaware limited liability company. This agreement grants Dr Reddy’s USA exclusive rights to commercialise Cyclophosphamide Injection RTD (500 mg/2.5mL; 1g/5mL; 2g/10mL) in the United States.

Under this agreement, Dr Reddy’s USA will distribute the product and share 50% of the calculated profits with Ingenus without any additional payments. According to IQVIA data, sales of this Ingenus product reached USD 51.8 million in the past 12 months up to March 2024.

Additionally, the companies will establish a commercial supply agreement where Ingenus will be the supplier of the product to Dr Reddy’s USA. This strategic collaboration aims to leverage Dr Reddy’s distribution capabilities and Ingenus’s product expertise to enhance market access and availability of Cyclophosphamide injection in the US pharmaceutical market.

The transaction involving Ingenus does not constitute a related party transaction for Dr Reddy’s Laboratories Ltd. Ingenus is confirmed not to be associated with the company, Dr Reddy’s USA, or any of their promoter groups or affiliated companies. This distinction is crucial as it ensures that the agreement between Dr Reddy’s USA and Ingenus operates independently of any potential conflicts of interest or insider influences, maintaining transparency and compliance with regulatory standards.

Earlier this month, Aurigene Pharmaceutical Services Limited, a Dr Reddy’s Laboratories Limited’s company, inaugurated a new biologics facility spanning 70,000 sq. ft. in Genome Valley, Hyderabad. This facility aims to support customers by providing services such as process and analytical development, along with small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early-stage clinical needs.

About Dr Reddy’s Laboratories Ltd 

Dr Reddy’s Laboratories Ltd is a prominent India-based pharmaceutical company that provides a portfolio of products and services, which includes Custom Pharmaceutical services (CPS), Active Pharmaceutical Ingredients (APIs), biosimilars, generics and differentiated formulations.

On June 13, 2024, the share price of Dr Reddy’s Laboratories Ltd opened at ₹6,119.90, touching the day’s high at ₹6,119.90, as of 9:36 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

Enjoy Zero Brokerage on Equity Delivery
Enjoy Zero Brokerage on Equity Delivery

Get the link to download the App

Send App Link
Open Free Demat Account!
Enjoy Zero Brokerage on Stock Investments.